Andrey Boldin

Andrey Boldin

Auto-generated profile, based on publicly available information

Andrey Boldin

Sechenov First Moscow State Medical University (Sechenov University) Moscow Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
MKMaria Kozhevnikova
Maria Kozhevnikova
EKEkaterina Korobkova
Ekaterina Korobkova
AKAnastasia Krivova
Anastasia Krivova
AKA. V. Kukharenko
A. V. Kukharenko
NMNatalia Moskaleva
Natalia Moskaleva
YBYuri Belenkov
Yuri Belenkov
Aim. Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective of this study was to explore the relationship between plasma BCAAs and different stages of cardiovascular disorders.Material and methods. In our cross-sectional study, plasma BCAAs (valine, leucine and isoleucine) in individuals without cardiovascular diseases (CVDs) (nonCVD group, total n=27, with n=16 healthy, but with metabolic disorders) were compared to patients diagnosed with CVDs [CVD group, total n=109, being n=61 hypertension (n=31 with signs of beginning of myocardial remodeling) and n=48 patients with coronary artery disease (CAD)].Results. The plasma concentration of BCAAs was significantly higher in the group of patients with cardiovascular disease compared with the healthy group (p<0.05 for all amino acids tested): valine concentration was 238.7 [219.6; 267.0] μM in the non-CVD group and 261.2 [233.8; 298.7] μM in the CVD group; leucine concentration was 134.8 [122.4; 153.2] μM and 146.8 [129.0; 166.6] μM, respectively; and isoleucine 72.7 [65.3; 84.4] μM and 81.7 [68.0; 96.2] μM, respectively. Leucine and isoleucine concentration levels were minimal in the healthy participant subgroup and maximal in the IBS patient subgroup. No statistically significant differences in BCAAs concentrations were found in the subgroups without CAD. Significant increases in concentrations were observed in the subgroups of patients with CAD as follows: valine concentration was 256.3 [219.0; 297.9] μM in hypertension group and 261.7 [236.5; 307.5] μM in CAD group; leucine concentration was 141.8 [123.5; 166.6] μM and 154.1 [134.7; 172.7] μM, respectively, and isoleucine 72.8 [65.7; 94.0] μM and 85.7 [74.9; 101.7] μM, respectively. BCAAs profiles in all participants with metabolic disorders had “good” diagnostic accuracy with area under the receiver operating characteristics curve being 0.72, 0.70 and 0.70 for valine, leucine and isoleucine, respectively.Conclusion. BCAAs concentrations are elevated with higher severity of the cardiovascular disorder and exhibit potential as early independent indicators of coronary artery disease.

20 December 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VVValeria Varzieva
Valeria Varzieva
ABAndrey Boldin
Andrey Boldin
KSKsenia Shestakova
Ksenia Shestakova
SBSabina Baskhanova
Sabina Baskhanova
VSViktor Samoylov
Viktor Samoylov
SASvetlana Appolonova
Svetlana Appolonova
Background. Metabolomics studies in oncology provide a deeper understanding of the biochemical processes associated with tumor growth and the body's response to treatment. In patients with lymphoma, systemic metabolic changes remain poorly understood despite their high clinical significance. Aim. To evaluate changes in the metabolomic profile of blood plasma in patients with lymphoma at various stages of polychemotherapy (PCT) and compare them to those of healthy volunteers. Materials and methods. The study included 18 patients with lymphoma from whom blood was collected before treatment and after the first and third courses of PCT. The control group included 30 healthy volunteers. The analysis was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) and included measurements of amino acids, tryptophan and arginine derivatives, and acylcarnitines. Statistical processing was performed using analysis of variance and principal component analysis. Results. Prior to therapy, patients showed characteristic metabolic disorders: activation of the kynurenine pathway of tryptophan metabolism, a decrease in arginine, and an increase in its methylated derivatives, as well as shifts in the amino acid and acylcarnitine profiles. During PCT, partial normalization of these indicators was observed, especially for the serotonin-melatonin cascade and kynurenine metabolites. Conclusion. Metabolomics analysis revealed characteristic biochemical changes in patients with lymphoma and their changes over time during treatment. The data obtained emphasize the potential of metabolomics as a tool for monitoring treatment effectiveness and patient condition in oncology.